The quarter saw continued double-digit revenue growth, marking the twelfth straight period of robust expansion. The Tyvaso product line -- which includes Tyvaso DPI (a dry powder inhaler for pulmonary hypertension) and nebulized Tyvaso (an inhaled formulation) -- delivered $469.6 million in combined sales. Tyvaso made up 58.8% of total company revenue. Tyvaso DPI revenue grew 22% year over year while nebulized Tyvaso climbed 10%. These gains were driven by more patients starting therapy and increased use fo ...